Kelly@ECP

Call for Papers from Experimental and Clinical Psychopharmacology. Special Issue on Real-World Challenges in Substance Use Behaviors: comorbidities, polysubstance use, and translational approaches. Clinical, preclinical, and population studies welcome. Deadline: July 1, 2026.

Call for Papers from Experimental and Clinical Psychopharmacology. Special Issue on Real-World Challenges in Substance Use Behaviors: comorbidities, polysubstance use, and translational approaches. Clinical, preclinical, and population studies welcome. Deadline: July 1, 2026.

Call for Papers from Experimental and Clinical Psychopharmacology. Special Issue on Real-World Challenges in Substance Use Behaviors: comorbidities, polysubstance use, and translational approaches. Clinical, preclinical, and population studies welcome. Deadline: July 1, 2026.

Call for Papers from Experimental and Clinical Psychopharmacology. Special Issue on Real-World Challenges in Substance Use Behaviors: comorbidities, polysubstance use, and translational approaches. Clinical, preclinical, and population studies welcome. Deadline: July 1, 2026.

Call for Papers from Experimental and Clinical Psychopharmacology. Special Issue on Real-World Challenges in Substance Use Behaviors: comorbidities, polysubstance use, and translational approaches. Clinical, preclinical, and population studies welcome. Deadline: July 1, 2026.

Call for Papers from Experimental and Clinical Psychopharmacology. Special Issue on Real-World Challenges in Substance Use Behaviors: comorbidities, polysubstance use, and translational approaches. Clinical, preclinical, and population studies welcome. Deadline: July 1, 2026.

Call for Papers from Experimental and Clinical Psychopharmacology. Special Issue on Real-World Challenges in Substance Use Behaviors: comorbidities, polysubstance use, and translational approaches. Clinical, preclinical, and population studies welcome. Deadline: July 1, 2026.

ECP introduces Consulting Editor Dr. Elise Weerts Ph.D., from the Johns Hopkins University School of Medicine. Follow us for late-breaking publications and submit your manuscripts at buff.ly/4gSm4ru

ECP introduces Consulting Editor Dr. Yukiko Washio Ph.D., BCBA-D from RTI International. Follow us for late-breaking publications and submit your manuscripts at buff.ly/4gSm4ru

Rzeszutek et al., outline a new demand model that prevents the need to remove the parameter k. Removal of this span parameter allows for uniform interpretation of results across commodities while still normalizing data across initial consumption value psycnet.apa.org/record/2025-85…

ECP introduces Consulting Editor Dr. Orrin Ware Ph.D. MPH, MSW, from the University of North Carolina Follow us for late-breaking publications and submit your manuscripts at buff.ly/4gSm4ru

ECP introduces Consulting Editor Dr. Antover Tuliao Ph.D., from Texas Tech University Follow us for late-breaking publications and submit your manuscripts at buff.ly/4gSm4ru

Gilroy et al., provide a comprehensive demonstration of how machine learning and reinforcement learning can directly assist in research related to substance use and various other domains employing behavioral economic methodologies. psycnet.apa.org/record/2025-84…

ECP introduces Consulting Editor Dr. D. Andrew Tompkins, M.D. from the University of California, San Francisco Follow us for late-breaking publications and submit your manuscripts at buff.ly/4gSm4ru

ECP introduces Consulting Editor Dr. Michael Taffe Ph.D., from the University of California, San Diego Follow us for late-breaking publications and submit your manuscripts at buff.ly/4gSm4ru

Verner et al., found patients with prescription opioid use disorder had greater spontaneous drug cravings and cravings elicited by prescription opioid stimuli vs. healthy controls and that cravings were associated with higher depression and anxiety ratings psycnet.apa.org/record/2025-63…

ECP introduces Consulting Editor Dr. WIlliam Stoops Ph.D., from the University of Kentucky Follow us for late-breaking publications and submit your manuscripts at buff.ly/4gSm4ru

ECP introduces Consulting Editor Dr. Justin Strickland Ph.D., from the Johns Hopkins University School of Medicine. Follow us for late-breaking publications and submit your manuscripts at buff.ly/4gSm4ru

Roszkowski et al., found therapeutic doses of alprazolam can produce next-day driving impairment, suggesting individuals may be unaware of next-day driving impairment and may unknowingly place themselves (and others) at risk. psycnet.apa.org/record/2025-46…

ECP introduces Consulting Editor Dr. Kirsten Elin Smith Ph.D., MSW from the Johns Hopkins University School of Medicine. Follow us for late-breaking publications and submit your manuscripts at buff.ly/4gSm4ru